Toppila, Iiro
Miettinen, Tatu
Lassenius, Mariann I.
Lievonen, Juha
Bauer, Melissa
Anttila, Pekka
Funding for this research was provided by:
Takeda Oy
Article History
Received: 23 December 2020
Accepted: 2 March 2021
First Online: 12 March 2021
Declarations
:
: <b>The study was approved by each register holder.</b>
: IT, MIL, and TM are employees of Medaffcon Oy; TM is and MB was an employee of Takeda Finland; JL has received consultation fees from Amgen, Celgene, Bristol-Myers Squibb, Sanofi, Takeda, Janssen, and travel grants from Janssen, Celgene, Amgen, Novartis, TEVA, Takeda, Roche, Abbvie, Pfizer; PA has been the Hematologist in charge for treatment of plasma cell malignancies at the Helsinki University Hospital and has received consultation fees from Amgen, BMS, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda and travel grants from AbbVie, Amgen, BMS, Celgene, Sanofi Genzyme, Janssen, Mundipharma, Novartis, Roche and Teva.